News | June 10, 2014

SPECT/CT Reveals Best Treatment for Low Back Pain

Molecular imaging solves the puzzle of patients’ pain prior to medical intervention

June 10, 2014 — Low back pain is not only excruciating but also debilitating for countless sufferers. Unfortunately, not everyone responds to treatment. A molecular imaging scan in addition to a conventional bone scan can provide the necessary information about the physiological health of the spine to select the most appropriate pain-killing treatment protocol, say researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting (SNMMI).

Conventional imaging methods including X-ray, computed tomography (CT) and even magnetic resonance imaging (MRI) show the structure of the bone, but the source of the pain is often not directly related to obvious structural changes. A hybrid molecular imaging approach called single photon emission computed tomography, combined with computed tomography (SPECT/CT), is able to go beyond structure to pinpoint the subtle physiological processes causing the pain — inflammation or infection, for example. With more clinical certainty, interventionalists can offer a range of treatments to relieve their patients’ suffering.

“Low back pain is an extremely common problem that affects most people at some point in their life,” said Suruchi Jain, co-author of the clinical study conducted at the Sanjay Gandhi Institute of Medical Sciences in Lucknow, India. “Inclusion of SPECT/CT with conventional bone scan could help reduce unnecessary treatments and provide vital information for the proper management of patients in pain.”

The aim of the study was to compare the difference in pain relief following clinical pain management between two groups of patients. A total of 80 adults between the ages of 20 and 80 years of age were included in the randomized, double-blind trial. One group underwent conventional bone scans with the addition of SPECT/CT, and a second group acted as a control, with no imaging provided prior to intervention. Patients were evaluated on a scale according to percentage of pain relief compared to their baseline level prior to treatment.

Patients with 50 percent or greater pain relief were much more likely to be in the bone scan group. A total of 28 patients in the bone scan group achieved between 70 and 100 percent pain relief, compared to only 10 subjects in that range in the control group. Clinical diagnosis was altered for 23 out of 40 patients in the bone scan group, and three new conditions were unveiled as a result of the bone scan. This evidence could improve access to SPECT/CT for these patients.

“The findings of this study suggest that incorporation of a bone scan with SPECT/CT in work-ups of low backache patients could lead to more widespread use of this nuclear medicine procedure in the future by increasing the confidence level of pain-treating physicians prior to interventions, thus improving their outcome,” Jain said.

For more information: www.snmmi.org

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...